Riskpilot← Back to searchSign inGet full accessBasic Genomics AB
ABActiveOrg 5593273211Nobels Väg 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20215-9 employees
Revenue 2024
SEK 0
EBITDA margin
—
+127% vs 2023
Equity ratio
85.2%
Financial strength
Net profit 2024
SEK 356K
+119% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 492K | +127% |
| Net profit | SEK 356K | +119% |
| Total assets | SEK 3,3M | -7% |
| Equity | SEK 2,8M | +14% |
| Employees | — | — |
Legal name
Basic Genomics AB
Org number
5593273211
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 juli 2021
Share capital
SEK 36 750
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla metoder, sälja reagens och tjänster inom biologisk och medicinsk forskning samt bedriva därmed förenlig verksamhet.
Address
Nobels Väg 16
Email
gert-jan.hendriks@basic-genomics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 270 | 0 | 0 |
| Staff expenses | — | −0 | −166 | −931 | −997 |
| EBITDA | −1 | −1 | −194 | −1 820 | 492 |
| Depreciation & amort. | −0 | −0 | −3 | −107 | −159 |
| EBIT | −1 | −0 | −197 | −1 927 | 334 |
| Net financials | — | 0 | 0 | 43 | 22 |
| Profit before tax | −1 | 1 | −197 | −1 884 | 356 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −1 | 1 | −197 | −1 884 | 356 |
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 29 | 29 | 4 648 | 3 564 | 3 316 |
| Equity | 29 | 29 | 4 354 | 2 470 | 2 826 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 0 | 0 | 294 | 1 094 | 491 |
| Total debt | — | 0 | 294 | 1 094 | 491 |
EBITDA margin
49231600.0%
This company
15.8%
Market median
+311592305% vs market
20212024
Equity ratio
85.2%
This company
38.2%
Market median
+123% vs market
20212024
Return on equity
12.6%
This company
18.4%
Market median
+32% vs market
20212024
Net profit margin
35609700.0%
This company
8.1%
Market median
+439625826% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-07-13 – 2021-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-07-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
HL | Audit | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Basic Genomics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gerardus Johannes Hendriks | Chief Executive Officer | 0 companies |
| Henrik Lars Ingvar Nilsson | Audit | 0 companies |
| Rickard Sandberg | Board of Directors | 0 companies |
| John Anton Magnus Larsson | Board of Directors | 0 companies |
| Johan Erik Simon Fredriksson | Chairman | 0 companies |